Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

키워드

참고문헌 (17)

1. Terry Cheuk-Fung Yip, "Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future", Clinical and Molecular Hepatology, 29, pp.171~183 (2023), 대한간학회
2. Davison BA, "Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials", J Hepatol, 73, pp.1322~1332 (2020)
3. Loo SY, "Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease", Hepatobiliary Surg Nutr, 6, pp.135~137 (2017)
4. Loomba R, "Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis", Gastroenterology, 156, pp.88~95 (2019)
5. Cusi K, "Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease", J Hepatol, 60, pp.167~174 (2014)
6. Chan WK, "Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers", PLoS One, 9, pp.e105903~ (2014)
7. Chuah KH, "MACK-3(combination of hoMa, Ast and CK18) : A promising novel biomarker for fibrotic non-alcoholic steatohepatitis", Liver Int, 39, pp.1315~1324 (2019)
8. Chong SE, "Validation of the Hepamet fibrosis score in a multi-ethnic Asian population", Ann Hepatol, 28, pp.100888~ (2022)
9. Newsome PN, "FibroScan-AST(FAST)score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.362~373 (2020)
10. Andersson A, "Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression : a multicenter pooled data and meta-analysis", Clin Gastroenterol Hepatol, 20, pp.2451~2461 (2022)
11. Le Berre C, "Application of artificial intelligence to gastroenterology and hepatology", Gastroenterology, 158, pp.76~94 (2020)
12. Fialoke S, "Application of machine learning methods to predict non-alcoholic steatohepatitis(NASH)in non-alcoholic fatty liver(NAFL)patients", AMIA Annu Symp Proc, 2018, pp.430~439 (2018)
13. Chan WK, "Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease", J Gastroenterol Hepatol, 37, pp.795~811 (2022)
14. Putrajaya: Malaysia Endocrine & Metabolic Society, "Clinical Practise Guidelines Management of Type 2 Diabetes Mellitus" (2020)
15. Chan WK, "A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis", Hepatol Int, 9, pp.594~602 (2015)
16. Chan WK, "Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis", Clin Gastroenterol Hepatol, 17, pp.2570~2580 (2019)
17. Chan WK, "Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative", Aliment Pharmacol Ther, 47, pp.816~825 (2018)

관련 논문AI추천